I-mab

Biotechnology • Healthcare • Rockville, MD, United States • IMAB (NGM)

I-Mab, a biotech company, focuses on the development of immuno-oncology agents for the treatment of cancer in the United States. The company is developing givastomig, a bispecific antibody, which is in Phase 1b clinical trial for the treatment of gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, a bispecific antibody, which is in phase 1 clinical trial for the treatment of solid tumors. It has a strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell, and offer to sell FE301, an interleukin-6 inhibitor. The company also has collaborations with Bristol Myers Squibb for the development of givastomig; ABL Bio, Inc. for the development of givastomig and ragistomig; and TJ Bio for the development of uliledlimab. I-Mab was founded in 2014 and is headquartered in Rockville, Maryland.

240 745 6330 2440 Research Boulevard, Rockville, MD 20850, United States

Stock Performance (90 Days)

Data through Dec 26, 2025

Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

I-Mab Biopharma Stock: Caution Warranted After Huge Surge (NASDAQ:IMAB) - Seeking Alpha

Seeking Alpha • Oct 14

I-Mab Is Suddenly Everywhere: Hidden Gem Stock or Total Trap? - AD HOC NEWS

AD HOC NEWS • Jan 6

I-Mab undergoes makeover, with new name, strategy, asset and Hong Kong IPO plans - Fierce Biotech

Fierce Biotech • Oct 17

I-Mab stock price target raised to $10 by Jefferies on rebranding, new asset - Investing.com

Investing.com • Oct 17

I-Mab (IMAB) Shows 83% Response Rate for Givastomig in Metastatic Gastric Cancer - Yahoo Finance

Yahoo Finance • Sep 23

Other Biotechnology Companies

Vertex Pharmaceuticals Inc. / MA

$118.68B market cap

Regeneron Pharmaceuticals, Inc.

$82.72B market cap

Alnylam Pharmaceuticals, Inc.

Frequently Asked Questions

Has I-Mab had layoffs?

No layoff events have been recorded for I-Mab in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.

How many employees does I-Mab have?

I-Mab has approximately 32 employees.

What industry is I-Mab in?

I-Mab operates in the Biotechnology industry, within the Healthcare sector.

Is I-Mab a publicly traded company?

Yes, I-Mab is publicly traded under the ticker symbol IMAB on the NGM. The company has a market capitalization of approximately $0.53 billion.

Where is I-Mab headquartered?

I-Mab is headquartered in Rockville, MD, United States at 2440 Research Boulevard, Rockville, MD 20850, United States.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.